Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM-020 gel in Seborrheic Keratosis
NCT06108024Phase 2Recruiting
- Sponsor
- DermBiont, Inc.
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in seborrheic keratosis (SK) comparing SM-020 gel 1.0% with Vehicle gel (2 arms). Primary endpoints: Proportion of all Seborrheic Keratosis Target Lesions (SKTLs) achieving a Physician's Lesion Assessment (PLA) score of 0 at 16 weeks, Severity of signs and symptoms of Application Site Reactions (ASRs) at 16 weeks and 1 more. Started Nov 2023; status: recruiting.
02
Drugs
SM-020
03
Conditions
seborrheic keratosis (SK)
Beyond the preview
Go deeper on NCT06108024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06108024.